The expanding universe of NUTM1 fusions in pediatric cancer
Clinical and Translational Science · 2023
DOI: 10.1111/cts.13535 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Rosane Charlab und 1 weiteren Autor:innen. Beteiligte Einrichtung: Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Carcinoma, Sarcoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
NUT midline carcinoma family member 1 ( NUTM1 ) fusions were originally identified in poorly differentiated and clinically aggressive carcinomas typically located in the midline structures of children and young adults, and collectively known as NUT (midline) carcinomas. Next‐generation sequencing later uncovered NUTM1 fusions in a variety of other pediatric and adult cancers of diverse location and type, including hematologic malignancies, cutaneous adnexal tumors, and sarcomas. A vast array of NUTM1 fusions with bromodomain containing 4 ( BRD4) or bromodomain containing 3 ( BRD3) , which are characteristic of NUT carcinoma, and with several other fusion partners have been identified and associated with variable prognosis. These non‐kinase fusions are thought to cause epigenetic reprogramming, thereby promoting proliferation, and hindering the differentiation of cancer cells. Many questions about both the function of the naïve NUTM1 protein, which is mostly restricted to the germ cells of the testis and is related to spermatogenesis and the oncogenic mechanisms of the various NUTM1 fusions in both adult and pediatric cancer, are still unanswered. Moreover, whether there is a relationship defined by the presence of NUTM1 fusions between conventional NUT carcinoma and other NUTM1 ‐rearranged neoplasms remains to be elucidated. This review will focus on recent discoveries of NUTM1 fusions found in pediatric cancers, their prognostic impact, and emergence as novel oncogenic drivers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Zitieren
APA
Charlab, R., & Racz, R. (2023). The expanding universe of NUTM1 fusions in pediatric cancer. Clinical and Translational Science. https://doi.org/10.1111/cts.13535
Vancouver
Charlab R, Racz R. The expanding universe of NUTM1 fusions in pediatric cancer. Clinical and Translational Science. 2023. doi:10.1111/cts.13535
BibTeX
@article{Charlab2023,
author = {Charlab, Rosane and Racz, Rebecca},
title = {The expanding universe of NUTM1 fusions in pediatric cancer},
journal = {Clinical and Translational Science},
year = {2023},
doi = {10.1111/cts.13535}
}
EUVIMED